for people ages 18-79 (full criteria)
at UCLAUC Davis
study started
estimated completion
Rajan Saggar (ucla) Roblee Allen (ucdavis)



This is an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who have completed Study TDE-HF-301. This study will provide long-term, open-label data regarding the effect of continued long-term oral treprostinil therapy for the treatment of pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Subject visits will occur at Baseline, Weeks 6, 12, 18, 24, and every 12 weeks thereafter until either oral treprostinil becomes commercially available to treat PH associated with HFpEF or the study is discontinued by the Sponsor.

Official Title

An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301


Pulmonary Hypertension Associated With HFpEFPulmonary HypertensionHFpEF6-Minute Walk TestOral TreprostinilHypertensionHeart FailureHypertension, PulmonaryTreprostinil


You can join if…

Open to people ages 18-79

  • The subject participated in Study TDE-HF-301, remained on study drug, was compliant with study procedures and assessments during Study TDE-HF-301, and completed through Week 24 of that study.

You CAN'T join if...

  • The subject is pregnant or lactating.
  • The subject was prematurely discontinued from Study TDE-HF-301 for any reason.
  • The subject developed a concurrent illness or condition during Study TDE HF 301, which, in the opinion of the Investigator, would represent a risk to the subject's overall health if they enrolled in this study.


  • University of California Los Angeles Pulmonary Division accepting new patients
    Los AngelesCalifornia90095United States
  • University of California - Davis Medical Center accepting new patients
    SacramentoCalifornia95817United States
  • VA Healthcare System of Greater Los Angeles accepting new patients
    Los AngelesCalifornia90073United States
  • Cedars-Sinai Medical Center accepting new patients
    Los AngelesCalifornia90211United States

Lead Scientists


accepting new patients
Start Date
Completion Date
United Therapeutics
Phase 3
Study Type
Last Updated